Ellagic acid derivatives from Rubus ulmifolius inhibit Staphylococcus aureus biofilm formation and improve response to antibiotics

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Quave, Cassandra L ^a   Estévez Carmona, Miriam ^b,c   Compadre, Cesar M ^b   Hobby, Gerren ^a   Hendrickson, Howard ^b   Beenken, Karen E ^a   Smeltzer, Mark S ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; DAPTOMYCIN; ELLAGIC ACID; ELLAGIC ACID MANNOPYRANOSIDE; ELLAGIC ACID XYLOFURANOSIDE; ELLAGIC ACID XYLOPYRANOSIDE; OXACILLIN; PLANT EXTRACT; RUBUS ULMIFOLIUS EXTRACT; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BIOFILM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESPONSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; KIDNEY CELL; LIVER CELL; MOUSE; NONHUMAN; PLANT ROOT; RAT; RUBUS; RUBUS ULMIFOLIUS; STAPHYLOCOCCUS AUREUS; TOXICITY TESTING; ANIMAL; ANTIBIOTIC PROPHYLAXIS; BIOASSAY; CELL DEATH; CELL LINE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG EFFECT; FRACTIONATION; GLYCOSYLATION; GROWTH, DEVELOPMENT AND AGING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROBIOLOGICAL EXAMINATION; PHYSIOLOGY; ROSACEAE;

BACTERIA (MICROORGANISMS); MAMMALIA; ROSACEAE; RUBUS ULMIFOLIUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BIOFILMS; BIOLOGICAL ASSAY; CELL DEATH; CELL LINE; CHEMICAL FRACTIONATION; CHROMATOGRAPHY, LIQUID; ELLAGIC ACID; GLYCOSYLATION; HUMANS; MASS SPECTROMETRY; MICE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, CONFOCAL; PLANT EXTRACTS; ROSACEAE; STAPHYLOCOCCUS AUREUS;

EID: 84855582460     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028737     Document Type: Article

References (60)

1. Yamamoto T, Nishiyama A, Takano T, Yabe S, Higuchi W, et al. (2010) Community-acquired methicillin-resistant Staphylococcus aureus: community transmission, pathogenesis, and drug resistance. Journal of Infection and Chemotherapy 16: 225-254.
2. Hildron AI, Low CE, Honig EG, Blumberg HM, (2009) Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. The Lancet Infectious Diseases 9: 384-392.
3. Klevens RM, Morrison M, Nadle J, Petit S, Gershman K, et al. (2007) Invasive Methicillin-Resistant Staphylococcus aureus infections in the United States. JAMA 298: 1763-1771.
4. Harro JM, Peters BM, O'May GA, Archer N, Kerns P, et al. (2010) Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration. FEMS Immunology and Medical Microbiology 59: 306-323.
5. Thomas JG, Litton I, Rinde H, (2006) Economic impact of biofilms on treatment costs. In: Pace JL, Rupp ME, Finch RG, editors. Biofilms, Infection and Antimicrobial Therapy Boca Raton, FL CRC Press. Taylor and Francis pp. 21-37.
6. Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE, (1982) Pathogenesis of foreign body infection: description and characteristics of an animal model. Journal of Infectious Diseases 146: 487-497.
7. Toms AD, Davidson D, Masri BA, Duncan CP, (2006) The management of peri-prosthetic infection in total joint arthroplasty. The Journal of Bone and Joint Surgery 88-B: 149-155.
8. Brause BD, (2005) Infections with prostheses in bones and joints. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practices of Infectious Diseases Washington, DC WB Saunders pp. 1332-1337.
9. Wolcott RD, Rhoads DD, Bennett ME, Gogokhia L, Costerton JW, et al. (2010) Chronic wounds and the medical biofilm paradigm. Journal of Wound Care 19: 45-53.
10. Wolcott RD, Dowd SE, (2010) The role of biofilms: are we hitting the right target? Plastic and Reconstructive Surgery 127: 28S-35S.
11. Kalan L, Wright GD, (2011) Antibiotic adjuvants: multicomponent anti-infective strategies. Expert Reviews in Molecular Medicine 13: null-null.
12. Cox PA, Balick MJ, (1994) The ethnobotanical approach to drug discovery. Scientific American 270: 82-87.
13. Howell A, Botto H, Combescure C, Blanc-Potard A-B, Gausa L, et al. (2010) Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infectious Diseases 10: 94.
14. Howell AB, (2007) Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Molecular Nutrition & Food Research 51: 732-737.
15. Pérez-López FR, Haya J, Chedraui P, (2009) Vaccinium macrocarpon: An interesting option for women with recurrent urinary tract infections and other health benefits. Journal of Obstetrics and Gynaecology Research 35: 630-639.
16. Low CF, Chong PP, Yong PVC, Lim CSY, Ahmad Z, et al. (2008) Inhibition of hyphae formation and SIR2 expression in Candida albicans treated with fresh Allium sativum (garlic) extract. Journal of Applied Microbiology 105: 2169-2177.
17. Bodini SF, Manfredini S, Epp M, Valentini S, Santori F, (2009) Quorum sensing inhibition activity of garlic extract and p-coumaric acid. Letters in Applied Microbiology 49: 551-555.
18. Harjai K, Kumar R, Singh S, (2010) Garlic blocks quorum sensing and attenuates the virulence of Pseudomonas aeruginosa. FEMS Immunology & Medical Microbiology 58: 161-168.
19. Fulghesu L, Giallorenzo C, Savoia D, (2007) Evaluation of Different Compounds as Quorum Sensing Inhibitors in Pseudomonas aeruginosa. Journal of Chemotherapy 19: 388-391.
20. Smith ECJ, Kaatz GW, Seo SM, Wareham N, Williamson EM, et al. (2007) The phenolic diterpene Totarol Inhibits multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother 51: 4480-4483.
21. Chérigo L, Pereda-Miranda R, Fragoso-Serrano M, Jacobo-Herrera N, Kaatz GW, et al. (2008) Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides. Journal of Natural Products 71: 1037-1045.
22. Wang W, Zeng YH, Osman K, Shinde K, Rahman M, et al. (2010) Norlignans, acylphloroglucinols, and a dimeric xanthone from Hypericum chinense. Journal of Natural Products 73: 1815-1820.
23. Gibbons S, (2004) Anti-staphylococcal plant natural products. Natural Product Reports 21: 263-277.
24. Gibbons S, (2008) Phytochemicals for bacterial resistance-strengths, weaknesses and opportunities. Planta Medica 74: 594-602.
25. Gibbons S, Ohlendorf B, Johnsen I, (2002) The genus Hypericum-a valuable resource of anti-Staphylococcal leads. Fitoterapia 73: 300-304.
26. Giusti EM, Pieroni A, Quave CL, (2004) Medical anthropology at the borders: ritual healing in Arbëreshë Albanian ethnic communities in Lucania (southern Italy). In: Paládi-Kovács A, Csukás G, Kiss R, Kristóf I, Nagy I, editors. Times, Places, Passages Ethnological Approaches in the New Millennium 7th SIEF Selected Papers Budapest, Hungary Akadémiai Kiadó pp. 237-245.
27. Quave CL, Plano LWR, Bennett BC, (2010) Quorum sensing inhibitors for MRSA from Italian medicinal plants. Planta Medica 76: 1-8.
28. Quave CL, Plano LWR, Pantuso T, Bennett BC, (2008) Effects of extracts from Italian medicinal plants on planktonic growth, biofilm formation and adherence of methicillin-resistant Staphylococcus aureus. Journal of Ethnopharmacology 118: 418-428.
29. Lin M-H, Chang F-R, Hua M-Y, Wu Y-C, Liu S-T, (2011) Inhibitory effects of 1,2,3,4,6-Penta-O-Galloyl-β-D-Glucopyranose on biofilm formation by Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 55: 1021-1027.
30. Alviano DS, Alviano CS, (2009) Plant Extracts: Search for New Alternatives to Treat Microbial Diseases Current Pharmaceutical Biotechnology 10: 106-121.
31. Flamini G, Catalano S, Caponi C, Panizzi L, Morelli I, (2002) Three anthrones from Rubus ulmifolius. Phytochemistry 59: 873-876.
32. Panizzi L, Caponi C, Catalano S, Cioni PL, Morelli I, (2002) In vitro antimicrobial activity of extracts and isolated constituents of Rubus ulmifolius. Journal of Ethnopharmacology 79: 165-168.
33. Quave CL, Pieroni A, Bennett BC, (2008) Dermatological remedies in the traditional pharmacopoeia of Vulture-Alto Bradano, inland southern Italy. Journal of Ethnobiology and Ethnomedicine 4: 5.
34. Weiss EC, Spencer HJ, Daily SJ, Weiss BD, Smeltzer MS, (2009) Impact of sarA on antibiotic susceptibility of Staphylococcus aureus in a catheter-associated in vitro model of biofilm formation. Antimicrobial Agents and Chemotherapy 53: 2475-2482.
35. Weiss EC, Zielinska A, Beenken KE, Spencer HJ, Daily SJ, et al. (2009) Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo. Antimicrobial Agents and Chemotherapy 53: 4096-4102.
36. Dall'Acqua S, Cervellati R, Loi MC, Innocenti G, (2008) Evaluation of in vitro antioxidant properties of some traditional Sardinian medicinal plants: Investigation of the high antioxidant capacity of Rubus ulmifolius. Food Chemistry 106: 745-749.
37. Landete JM, (2011) Ellagitannins, ellagic acid and their derived metabolites: A review about source, metabolism, functions and health. Food Research International 44: 1150-1160.
38. Zafrilla P, Ferreres F, Tomas-Barberan FA, (2001) Effect of processing and storage on the antioxidant ellagic acid derivatives and flavonoids of red raspberry (Rubus idaeus) jams. Journal of Agricultural and Food Chemistry 49: 3651-3655.
39. Lee J-H, Talcott ST, (2003) Fruit maturity and juice extraction influences ellagic acid derivatives and other antioxidant polyphenolics in muscadine grapes. Journal of Agricultural and Food Chemistry 52: 361-366.
40. Losso JN, Bansode RR, Trappey A, Bawadi HA, Truax R, (2004) In vitro anti-proliferative activities of ellagic acid. The Journal of Nutritional Biochemistry 15: 672-678.
41. Papoutsi Z, Kassi E, Tsiapara A, Fokialakis N, Chrousos GP, et al. (2005) Evaluation of estrogenic/antiestrogenic activity of ellagic acid via the estrogen receptor subtypes ERα and ERβ. Journal of Agricultural and Food Chemistry 53: 7715-7720.
42. Umesalma S, Sudhandiran G, (2010) Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-κB, iNOS, COX-2, TNF-α, and IL-6 in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Basic & Clinical Pharmacology & Toxicology 107: 650-655.
43. Weidner-Wells MA, Altom J, Fernandez J, Fraga-Spano SA, Hilliard J, et al. (1998) DNA gyrase inhibitory activity of ellagic acid derivatives. Bioorganic & Medicinal Chemistry Letters 8: 97-100.
44. Cozza G, Bonvini P, Zorzi E, Poletto G, Pagano MA, et al. (2006) Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. Journal of Medicinal Chemistry 49: 2363-2366.
45. Hancock V, Dahl M, Vejborg RM, Klemm P, (2010) Dietary plant components ellagic acid and tannic acid inhibit Escherichia coli biofilm formation. Journal of Medical Microbiology 59: 496-498.
46. Huber B, Eberl L, Feucht W, Polster J, (2003) Influence of polyphenols on bacterial biofilm formation and quorum-sensing. Zeitschrift für Naturforschung 58c: 879-884.
47. Dürig A, Kouskoumvekaki I, Vejborg R, Klemm P, (2010) Chemoinformatics-assisted development of new anti-biofilm compounds. Applied Microbiology and Biotechnology 87: 309-317.
48. Simões-Pires CA, Vargas S, Marston A, Ioset JR, Paulo MQ, et al. (2009) Ellagic acid derivatives from Syzygium cumini stem bark: investigation of their antiplasmodial activity. Natural Product Communications 4: 1371-1376.
49. Elkhateeb A, Subeki TK, Matsuura H, Yamasaki M, Yamato O, et al. (2005) Anti-babesial ellagic acid rhamnosides from the bark of Elaeocarpus parvifolius. Phytochemistry 66: 2577-2580.
50. Atta-Ur-Rahman NFN, Choudhary MI, Malik S, Makhmoor T, Nur-E-Alam M, et al. (2001) New antioxidant and antimicrobial ellagic acid derivatives from Pteleopsis hylodendron. Planta Medica 67: 335-339.
51. Matthew S, Kao KC, Chang YS, Abreu P, (2007) Ellagic acid glycosides from Turpinia ternata. Natural Product Research 21: 83-88.
52. Beenken KE, Mrak LN, Griffin LM, Zielinska A, Shaw LN, et al. (2010) Epistatic relationships between sarA and agr in Staphylococcus aureus biofilm formation. PLoS ONE 5.
53. Beenken KE, Blevins JS, Smeltzer MS, (2003) Mutation of sarA in Staphylococcus aureus limits biofilm formation. Infection and Immunity 71: 4206-4211.
54. Tsang LH, Cassat JE, Shaw LN, Beenken KE, Smeltzer MS, (2008) Factors contributing to the biofilm-deficient phenotype of Staphylococcus aureus sarA mutants. PLoS One 3: e3361.
55. WHO (2003) WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. Geneva.
56. Pignatti S, (2002) Flora d'Italia Bologna, Italy Edizioni Edagricole.
57. Isenberg HD, (2004) Clinical Microbiology Procedures Handbook; In: Isenberg HD, editors. Washington, D.C. ASM Press.
58. NCCLSNCCLS, editor (1999) Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline; Wayne, PA National Committee for Clinical Laboratory Standards.
59. NCCLS (2001) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard Wayne, PA National Center for Clinical Laboratory Standards.
60. Ernest S, Bello-Reuss E, (1995) Expression and function of P-glycoprotein in a mouse kidney cell line. American Journal of Physiology- Cell Physiology 269: C323-C333.